Veracyte Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
Go back to Veracyte Announces First Quarter 2021 Financial Results
May 11, 2021 6:34 AM EDT
Needham & Company analyst Stephen Unger lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $54.00 (from $88.00) while maintaining a Buy rating.
The analyst commented, "VCYT's 1Q21 revenue was in line with its 4/16/21 preannouncement and EPS adjusted for one-time acquisition expenses beat consensus. Organic... More
May 10, 2021 4:31 PM EDT
Veracyte (NASDAQ: VCYT) reported Q1 EPS of $0.66, $0.78 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $36.7 million versus the consensus estimate of $32.67 million.
Total Revenue was $36.7 million, including $3.8 million for urologic cancer testing, an increase of 18%;Gross Margin was 66%;Operating Expenses were $82.1 million. Operating Expenses, Excluding Cost of Revenue, were $69.7 million, including $35.1 million related to...
More
